Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment.
Wollenberg A, Reitamo S, Atzori F, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M; European Tacrolimus Ointment Study Group. Wollenberg A, et al. Among authors: lahfa m. Allergy. 2008 Jun;63(6):742-50. doi: 10.1111/j.1398-9995.2008.01683.x. Allergy. 2008. Corrected and republished in: Allergy. 2008 Jul;63(7):742-50.. PMID: 18445188 Corrected and republished. Clinical Trial.
Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial.
Sterry W, Stingl G, Langley RG, Zacharie H, Lahfa M, Giannetti A, Ferrándiz C, Sinclair R, Saurat JH; CLEAR Multinational Study Group. Sterry W, et al. Among authors: lahfa m. J Dtsch Dermatol Ges. 2006 Nov;4(11):947-56. doi: 10.1111/j.1610-0387.2006.06111.x. J Dtsch Dermatol Ges. 2006. PMID: 17081270 Clinical Trial. English, German.
Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment.
Doss N, Kamoun MR, Dubertret L, Cambazard F, Remitz A, Lahfa M, de Prost Y. Doss N, et al. Among authors: lahfa m. Pediatr Allergy Immunol. 2010 Mar;21(2 Pt 1):321-9. doi: 10.1111/j.1399-3038.2009.00895.x. Epub 2009 Jun 26. Pediatr Allergy Immunol. 2010. PMID: 19563466 Clinical Trial.
Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial.
Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, Kaszuba A, Bissonnette R, Varjonen E, Holló P, Cambazard F, Lahfa M, Elsner P, Nyberg F, Svensson A, Brown TC, Harsch M, Maares J. Ruzicka T, et al. Among authors: lahfa m. Br J Dermatol. 2008 Apr;158(4):808-17. doi: 10.1111/j.1365-2133.2008.08487.x. Epub 2008 Feb 21. Br J Dermatol. 2008. PMID: 18294310 Clinical Trial.
0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study.
Ortonne JP, van de Kerkhof PC, Prinz JC, Bieber T, Lahfa M, Rubins A, Wozel G, Lorette G; European Tacrolimus Psoriasis Study Group. Ortonne JP, et al. Among authors: lahfa m. Acta Derm Venereol. 2006;86(1):29-33. doi: 10.1080/00015550510039817. Acta Derm Venereol. 2006. PMID: 16585986 Free article. Clinical Trial.
Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial.
Goujon C, Viguier M, Staumont-Sallé D, Bernier C, Guillet G, Lahfa M, Ferrier Le Bouedec MC, Cambazard F, Bottigioli D, Grande S, Dahel K, Bérard F, Rabilloud M, Mercier C, Nicolas JF. Goujon C, et al. Among authors: lahfa m. J Allergy Clin Immunol Pract. 2018 Mar-Apr;6(2):562-569.e3. doi: 10.1016/j.jaip.2017.07.007. Epub 2017 Sep 28. J Allergy Clin Immunol Pract. 2018. PMID: 28967549 Clinical Trial.
54 results